Induction Healthcare Group
PLC
Full Year Trading
Update
London, UK - 29 April 2024: Induction
Healthcare Group PLC ("Induction", the "Company", or
the "Group"; AIM: INHC), a leading digital
health platform driving transformation of healthcare systems, today
announces the following trading update for the year ending 31 March
2024.
Financial Highlights (unaudited)
· Revenues of approximately £14.1m (FY23: £13.6m), broken down
as follows:
o Attend Anywhere: £8.5m
o Zesty: £4.9m
o Guidance: £0.7m
· Adjusted EBITDA* expected to be in line with market
expectation at approximately £0.3m (FY23: -£3.6m)
· Gross
margin improvement to 77.9% (FY23: 63.1%)
· Net
cash £3.7m (31 March 2023: £4.3m)
* Adjusted
EBITDA is Operating result from continuing operations before
depreciation (£0.1m), amortisation (£4.3m) and net of non-cash/
non-operating items (£0.2m)
Operational Highlights
· New
NHS patient portal contracts compensate for downward pressure on
video pricing.
· Completed effective cost containment and margin enhancement
programme.
· Achieved objective of self-sustaining growth and cash flow
breakeven.
· Signed
a total of £3.4m (includes previously-announced contracts) in
contracts with NHS England Trusts to:
o Further integrate Zesty with Oracle Cerner and widely-used
diagnostic booking systems (Cris and Soliton);
o Enhance Form Builder module to support waitlist validation;
and
o Build new functionality, such as digitising maternity
records.
All platform and product
enhancements underpin valuable upsell opportunities for
FY25.
· Launched Zesty in 4 new Trusts, including a new contract award
in Q4 with George Elliot Hospital NHS Trust. Three additional
Trusts are contracted to launch Zesty within the next 12
months.
· Successfully built and launched the first phase of our
integrated product which enables a patient to view and launch their
Attend Anywhere consultation from within Zesty. Five customers have
already purchased the integrated functionality.
· NHS
Wales agreed to a 9-month extension for £730,858 in order to
prepare for a new procurement, which was expected under NHS
procurement rules given the length of a new contract.
Induction expects to release its
audited results for the year ending 31 March 2024 on 1 July
2024.
Paul Tambeau, CEO of Induction Healthcare
said: "Our key focus this year was to stabilise the
business, complete a cost containment programme, and put Induction
onto a self-sustaining path without the need for immediate funding.
I'm very pleased that we have delivered on these objectives. We
also delivered on integrating our video and portal platforms,
divesting a non-strategic asset, and building out new functionality
that will position the company well for future growth. While we
continue to see downward pressure on pricing for Attend Anywhere,
the number of Trusts moving to our main competitor remains low. We
see opportunities to work ever closer with Trusts to Increase the
adoption of our integrated video and portal product and to further
develop modules that will increase both reach and effectiveness
across the healthcare spectrum in the UK.
Enquiries
Induction
Christopher Samler, Chair
Paul Tambeau, Chief Executive
Officer
|
+44 (0)7712 194092
+44 (0)7983 104443
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
+44 (0)20 7496 3000
|
|
Philip Davies
Alaina Wong
Jalini Kalaravy
|
|
|
About Induction
- www.inductionhealthcare.com
Induction (AIM: INHC) Induction
delivers a suite of software solutions that transforms care
delivery and the patient journey through hospital. Our system-wide
applications help healthcare providers and administrators to
deliver care at any stage remotely as well as face-to-face - giving
the communities they serve greater flexibility, control and ease of
access. Purpose-built for integration with leading Electronic
Medical Record (EMR) platforms, our products offer immediate
stand-alone value that becomes even greater when integrated with
pre-existing systems.
Used at scale by national and
regional healthcare systems, as well non-health government
services, our applications are relied upon by hundreds of thousands
of clinicians and millions of patients across almost every hospital
in the British Isles.